Identification

Name
Methsuximide
Accession Number
DB05246
Type
Small Molecule
Groups
Approved
Description

Mesuximide (or methsuximide) is an anticonvulsant medication. It is sold by Pfizer under the name Petinutin. [Wikipedia]

Structure
Thumb
Synonyms
  • (RS)-1,3-Dimethyl-3-phenyl-2,5-pyrrolidindion
  • 1,3-Dimethyl-3-phenyl-2,5-dioxopyrrolidine
  • 1,3-Dimethyl-3-phenyl-2,5-pyrrolidinedione
  • 1,3-Dimethyl-3-phenyl-pyrrolidin-2,5-dione
  • 1,3-Dimethyl-3-phenylsuccinimide
  • Alpha-methyl-alpha-phenyl n-methyl succinimide
  • Alpha-methylphensuximide
  • Mesuximida
  • Mesuximide
  • Mesuximidum
  • Methsuximid
  • Metosuccimmide
  • Metsuccimide
  • N-methyl-alpha-methyl-alpha-phenylsuccinimide
  • N,2-Dimethyl-2-phenylsuccinimide
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
CelontinCapsule300 mg/1OralParke Davis Div Of Pfizer Inc1957-02-08Not applicableUs
Celontin Cap 300mgCapsule300 mgOralErfa Canada 2012 Inc1957-12-312015-06-05Canada
International/Other Brands
Celontin / Petinutin
Categories
UNII
0G76K8X6C0
CAS number
77-41-8
Weight
Average: 203.2371
Monoisotopic: 203.094628665
Chemical Formula
C12H13NO2
InChI Key
AJXPJJZHWIXJCJ-UHFFFAOYSA-N
InChI
InChI=1S/C12H13NO2/c1-12(9-6-4-3-5-7-9)8-10(14)13(2)11(12)15/h3-7H,8H2,1-2H3
IUPAC Name
1,3-dimethyl-3-phenylpyrrolidine-2,5-dione
SMILES
CN1C(=O)CC(C)(C1=O)C1=CC=CC=C1

Pharmacology

Indication

For the control of absence (petit mal) seizures that are refractory to other drugs.

Associated Conditions
Pharmacodynamics

Used in the treatment of epilepsy. Methsuximide suppresses the paroxysmal three cycle per second spike and wave activity associated with lapses of consciousness which is common in absence (petit mal) seizures. The frequency of epileptiform attacks is reduced, apparently by depression of the motor cortex and elevation of the threshold of the central nervous system to convulsive stimuli.

Mechanism of action

Binds to T-type voltage sensitive calcium channels. Voltage-sensitive calcium channels (VSCC) mediate the entry of calcium ions into excitable cells and are also involved in a variety of calcium-dependent processes, including muscle contraction, hormone or neurotransmitter release, gene expression, cell motility, cell division and cell death. The isoform alpha-1G gives rise to T-type calcium currents. T-type calcium channels belong to the "low-voltage activated (LVA)" group and are strongly blocked by mibefradil. A particularity of this type of channels is an opening at quite negative potentials and a voltage-dependent inactivation. T-type channels serve pacemaking functions in both central neurons and cardiac nodal cells and support calcium signaling in secretory cells and vascular smooth muscle. They may also be involved in the modulation of firing patterns of neurons which is important for information processing as well as in cell growth processes.

TargetActionsOrganism
AVoltage-dependent T-type calcium channel subunit alpha-1G
inhibitor
Human
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life

1.4-2.6 hours for mesuximide and 28-38 hours for the active metabolite.

Clearance
Not Available
Toxicity

Acute overdoses may produce nausea, vomiting, and CNS depression including coma with respiratory depression. Levels greater than 40 µg/mL have caused toxicity and coma has been seen at levels of 150 µg/mL.

Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
2-HYDROXY-1,4-NAPHTHOQUINONEThe therapeutic efficacy of 2-HYDROXY-1,4-NAPHTHOQUINONE can be increased when used in combination with Methsuximide.Experimental
2-mercaptobenzothiazoleThe therapeutic efficacy of 2-mercaptobenzothiazole can be increased when used in combination with Methsuximide.Vet Approved
7-NitroindazoleThe risk or severity of adverse effects can be increased when Methsuximide is combined with 7-Nitroindazole.Experimental
AbirateroneThe metabolism of Methsuximide can be decreased when combined with Abiraterone.Approved
AcepromazineThe risk or severity of adverse effects can be increased when Methsuximide is combined with Acepromazine.Approved, Vet Approved
AceprometazineThe risk or severity of adverse effects can be increased when Methsuximide is combined with Aceprometazine.Approved
AdipiplonThe risk or severity of adverse effects can be increased when Methsuximide is combined with Adipiplon.Investigational
AgomelatineThe risk or severity of adverse effects can be increased when Methsuximide is combined with Agomelatine.Approved, Investigational
AlaproclateThe risk or severity of adverse effects can be increased when Methsuximide is combined with Alaproclate.Experimental
AlfaxaloneThe risk or severity of adverse effects can be increased when Methsuximide is combined with Alfaxalone.Vet Approved
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Methsuximide.Approved, Illicit
AlfuzosinThe risk or severity of hypotension can be increased when Alfuzosin is combined with Methsuximide.Approved, Investigational
AllopregnanoloneThe risk or severity of adverse effects can be increased when Methsuximide is combined with Allopregnanolone.Investigational
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Methsuximide is combined with Alphacetylmethadol.Experimental, Illicit
AlphaprodineThe risk or severity of adverse effects can be increased when Methsuximide is combined with Alphaprodine.Illicit
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Methsuximide.Approved, Illicit, Investigational
AmisulprideThe risk or severity of adverse effects can be increased when Methsuximide is combined with Amisulpride.Approved, Investigational
AmitriptylineThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Methsuximide.Approved
AmobarbitalThe risk or severity of adverse effects can be increased when Amobarbital is combined with Methsuximide.Approved, Illicit
AmorolfineThe therapeutic efficacy of Amorolfine can be increased when used in combination with Methsuximide.Approved, Investigational
AmoxapineThe risk or severity of adverse effects can be increased when Amoxapine is combined with Methsuximide.Approved
AmperozideThe risk or severity of adverse effects can be increased when Methsuximide is combined with Amperozide.Experimental
Amphotericin BThe therapeutic efficacy of Amphotericin B can be increased when used in combination with Methsuximide.Approved, Investigational
AnidulafunginThe therapeutic efficacy of Anidulafungin can be increased when used in combination with Methsuximide.Approved, Investigational
ApalutamideThe serum concentration of Methsuximide can be decreased when it is combined with Apalutamide.Approved, Investigational
AripiprazoleThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Methsuximide.Approved, Investigational
ArmodafinilThe metabolism of Methsuximide can be decreased when combined with Armodafinil.Approved, Investigational
ArotinololThe risk or severity of hypotension, conduction block, and bradycardia can be increased when Arotinolol is combined with Methsuximide.Investigational
ArtemetherThe therapeutic efficacy of Artemether can be increased when used in combination with Methsuximide.Approved
ArticaineThe risk or severity of adverse effects can be increased when Methsuximide is combined with Articaine.Approved
AsenapineThe risk or severity of adverse effects can be increased when Asenapine is combined with Methsuximide.Approved
AzaperoneThe risk or severity of adverse effects can be increased when Methsuximide is combined with Azaperone.Investigational, Vet Approved
AzelastineMethsuximide may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
BaclofenThe risk or severity of adverse effects can be increased when Baclofen is combined with Methsuximide.Approved
Bafilomycin A1The therapeutic efficacy of Bafilomycin A1 can be increased when used in combination with Methsuximide.Experimental
BarbexacloneThe metabolism of Methsuximide can be increased when combined with Barbexaclone.Experimental
BarbitalThe risk or severity of adverse effects can be increased when Methsuximide is combined with Barbital.Illicit
BenperidolThe risk or severity of adverse effects can be increased when Methsuximide is combined with Benperidol.Approved, Investigational
BenzocaineThe risk or severity of adverse effects can be increased when Methsuximide is combined with Benzocaine.Approved, Investigational
Benzoic AcidThe therapeutic efficacy of Benzoic Acid can be increased when used in combination with Methsuximide.Approved, Investigational
Benzyl alcoholThe risk or severity of adverse effects can be increased when Methsuximide is combined with Benzyl alcohol.Approved
BevantololThe risk or severity of hypotension can be increased when Bevantolol is combined with Methsuximide.Approved
BifonazoleThe therapeutic efficacy of Bifonazole can be increased when used in combination with Methsuximide.Approved, Investigational
BortezomibThe metabolism of Methsuximide can be decreased when combined with Bortezomib.Approved, Investigational
Brefeldin AThe therapeutic efficacy of Brefeldin A can be increased when used in combination with Methsuximide.Experimental
BrexpiprazoleThe risk or severity of adverse effects can be increased when Methsuximide is combined with Brexpiprazole.Approved, Investigational
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Methsuximide.Approved
BromazepamThe risk or severity of adverse effects can be increased when Bromazepam is combined with Methsuximide.Approved, Illicit, Investigational
BromisovalThe risk or severity of adverse effects can be increased when Methsuximide is combined with Bromisoval.Experimental
BromperidolThe risk or severity of adverse effects can be increased when Methsuximide is combined with Bromperidol.Approved, Investigational
BrompheniramineThe risk or severity of adverse effects can be increased when Brompheniramine is combined with Methsuximide.Approved
BrotizolamThe risk or severity of adverse effects can be increased when Methsuximide is combined with Brotizolam.Approved, Investigational, Withdrawn
BucindololThe risk or severity of hypotension can be increased when Bucindolol is combined with Methsuximide.Investigational
BunazosinThe risk or severity of hypotension can be increased when Bunazosin is combined with Methsuximide.Investigational
BupivacaineThe risk or severity of adverse effects can be increased when Methsuximide is combined with Bupivacaine.Approved, Investigational
BuprenorphineMethsuximide may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Methsuximide.Approved, Investigational
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Methsuximide.Approved, Illicit
ButacaineThe risk or severity of adverse effects can be increased when Methsuximide is combined with Butacaine.Vet Approved
ButalbitalThe risk or severity of adverse effects can be increased when Butalbital is combined with Methsuximide.Approved, Illicit
ButambenThe risk or severity of adverse effects can be increased when Methsuximide is combined with Butamben.Approved, Withdrawn
ButenafineThe therapeutic efficacy of Butenafine can be increased when used in combination with Methsuximide.Approved
ButethalThe risk or severity of adverse effects can be increased when Methsuximide is combined with Butethal.Approved, Illicit
ButoconazoleThe therapeutic efficacy of Butoconazole can be increased when used in combination with Methsuximide.Approved
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Methsuximide.Approved, Illicit, Vet Approved
Calcium AcetateThe therapeutic efficacy of Methsuximide can be decreased when used in combination with Calcium Acetate.Approved, Investigational
Calcium CarbonateThe therapeutic efficacy of Methsuximide can be decreased when used in combination with Calcium Carbonate.Approved, Investigational
Calcium ChlorideThe therapeutic efficacy of Methsuximide can be decreased when used in combination with Calcium Chloride.Approved
Calcium CitrateThe therapeutic efficacy of Methsuximide can be decreased when used in combination with Calcium Citrate.Approved
Calcium glubionateThe therapeutic efficacy of Methsuximide can be decreased when used in combination with Calcium glubionate.Approved
Calcium GluceptateThe therapeutic efficacy of Methsuximide can be decreased when used in combination with Calcium Gluceptate.Approved
Calcium gluconateThe therapeutic efficacy of Methsuximide can be decreased when used in combination with Calcium gluconate.Approved, Vet Approved
Calcium lactateThe therapeutic efficacy of Methsuximide can be decreased when used in combination with Calcium lactate.Approved, Investigational, Vet Approved
Calcium lactate gluconateThe therapeutic efficacy of Methsuximide can be decreased when used in combination with Calcium lactate gluconate.Experimental
Calcium levulinateThe therapeutic efficacy of Methsuximide can be decreased when used in combination with Calcium levulinate.Approved, Experimental
Calcium pangamateThe therapeutic efficacy of Methsuximide can be decreased when used in combination with Calcium pangamate.Experimental
Calcium PhosphateThe therapeutic efficacy of Methsuximide can be decreased when used in combination with Calcium Phosphate.Approved
CandicidinThe therapeutic efficacy of Candicidin can be increased when used in combination with Methsuximide.Withdrawn
CanertinibThe risk or severity of adverse effects can be increased when Methsuximide is combined with Canertinib.Investigational
Capric acidThe therapeutic efficacy of Capric acid can be increased when used in combination with Methsuximide.Experimental
CarbamazepineThe metabolism of Methsuximide can be increased when combined with Carbamazepine.Approved, Investigational
CarbinoxamineThe risk or severity of adverse effects can be increased when Carbinoxamine is combined with Methsuximide.Approved
CarfentanilThe risk or severity of adverse effects can be increased when Methsuximide is combined with Carfentanil.Illicit, Investigational, Vet Approved
CarisoprodolThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Methsuximide.Approved
CarvedilolThe risk or severity of hypotension can be increased when Carvedilol is combined with Methsuximide.Approved, Investigational
CaseinThe therapeutic efficacy of Methsuximide can be decreased when used in combination with Casein.Approved
CaspofunginThe therapeutic efficacy of Caspofungin can be increased when used in combination with Methsuximide.Approved
CeruleninThe therapeutic efficacy of Cerulenin can be increased when used in combination with Methsuximide.Approved
CetirizineThe risk or severity of adverse effects can be increased when Cetirizine is combined with Methsuximide.Approved
Chloral hydrateThe risk or severity of adverse effects can be increased when Methsuximide is combined with Chloral hydrate.Approved, Illicit, Investigational, Vet Approved
ChloramphenicolThe metabolism of Methsuximide can be decreased when combined with Chloramphenicol.Approved, Vet Approved
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Methsuximide.Approved, Illicit, Investigational
ChlormezanoneThe risk or severity of adverse effects can be increased when Methsuximide is combined with Chlormezanone.Approved, Investigational, Withdrawn
ChloroprocaineThe risk or severity of adverse effects can be increased when Methsuximide is combined with Chloroprocaine.Approved
ChloroxineThe therapeutic efficacy of Chloroxine can be increased when used in combination with Methsuximide.Approved
ChlorphenamineThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Methsuximide.Approved
ChlorpromazineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Methsuximide.Approved, Investigational, Vet Approved
ChlorprothixeneThe risk or severity of adverse effects can be increased when Methsuximide is combined with Chlorprothixene.Approved, Investigational, Withdrawn
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Methsuximide.Approved
CholecalciferolThe metabolism of Methsuximide can be decreased when combined with Cholecalciferol.Approved, Nutraceutical
CiclopiroxThe therapeutic efficacy of Ciclopirox can be increased when used in combination with Methsuximide.Approved, Investigational
CilostazolThe serum concentration of Cilostazol can be increased when it is combined with Methsuximide.Approved, Investigational
CimetidineThe serum concentration of Methsuximide can be increased when it is combined with Cimetidine.Approved, Investigational
CinchocaineThe risk or severity of adverse effects can be increased when Methsuximide is combined with Cinchocaine.Approved, Vet Approved
CitalopramThe metabolism of Methsuximide can be decreased when combined with Citalopram.Approved
ClemastineThe risk or severity of adverse effects can be increased when Clemastine is combined with Methsuximide.Approved, Investigational
ClidiniumThe risk or severity of adverse effects can be increased when Clidinium is combined with Methsuximide.Approved
ClobazamThe risk or severity of adverse effects can be increased when Clobazam is combined with Methsuximide.Approved, Illicit
clomethiazoleThe risk or severity of adverse effects can be increased when Methsuximide is combined with clomethiazole.Investigational
ClomipramineThe risk or severity of adverse effects can be increased when Clomipramine is combined with Methsuximide.Approved, Investigational, Vet Approved
ClonazepamThe risk or severity of adverse effects can be increased when Clonazepam is combined with Methsuximide.Approved, Illicit
ClonidineThe risk or severity of adverse effects can be increased when Clonidine is combined with Methsuximide.Approved
ClopenthixolThe risk or severity of adverse effects can be increased when Methsuximide is combined with Clopenthixol.Experimental
ClopidogrelThe therapeutic efficacy of Clopidogrel can be decreased when used in combination with Methsuximide.Approved
ClorazepateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Methsuximide.Approved, Illicit
ClothiapineThe risk or severity of adverse effects can be increased when Methsuximide is combined with Clothiapine.Experimental
ClotrimazoleThe metabolism of Methsuximide can be decreased when combined with Clotrimazole.Approved, Vet Approved
ClozapineThe risk or severity of adverse effects can be increased when Clozapine is combined with Methsuximide.Approved
CocaineThe risk or severity of adverse effects can be increased when Methsuximide is combined with Cocaine.Approved, Illicit
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Methsuximide.Approved, Illicit
CordycepinThe therapeutic efficacy of Cordycepin can be increased when used in combination with Methsuximide.Investigational
CyclizineThe risk or severity of adverse effects can be increased when Cyclizine is combined with Methsuximide.Approved
CyclobenzaprineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Methsuximide.Approved
CyclopropaneThe risk or severity of adverse effects can be increased when Methsuximide is combined with Cyclopropane.Experimental
CyclosporineThe therapeutic efficacy of Cyclosporine can be increased when used in combination with Methsuximide.Approved, Investigational, Vet Approved
CyproheptadineThe risk or severity of adverse effects can be increased when Cyproheptadine is combined with Methsuximide.Approved
DabrafenibThe serum concentration of Methsuximide can be decreased when it is combined with Dabrafenib.Approved, Investigational
DantroleneThe risk or severity of adverse effects can be increased when Dantrolene is combined with Methsuximide.Approved, Investigational
DapiprazoleThe risk or severity of adverse effects can be increased when Methsuximide is combined with Dapiprazole.Approved
DapoxetineThe risk or severity of adverse effects can be increased when Methsuximide is combined with Dapoxetine.Investigational
DelavirdineThe metabolism of Methsuximide can be decreased when combined with Delavirdine.Approved
DeramciclaneThe risk or severity of adverse effects can be increased when Methsuximide is combined with Deramciclane.Investigational
DesfluraneThe risk or severity of adverse effects can be increased when Desflurane is combined with Methsuximide.Approved
DesipramineThe risk or severity of adverse effects can be increased when Desipramine is combined with Methsuximide.Approved, Investigational
DesloratadineThe risk or severity of adverse effects can be increased when Desloratadine is combined with Methsuximide.Approved, Investigational
DesvenlafaxineThe risk or severity of adverse effects can be increased when Methsuximide is combined with Desvenlafaxine.Approved, Investigational
DetomidineThe risk or severity of adverse effects can be increased when Methsuximide is combined with Detomidine.Vet Approved
DexbrompheniramineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Methsuximide.Approved
DexmedetomidineThe risk or severity of adverse effects can be increased when Methsuximide is combined with Dexmedetomidine.Approved, Vet Approved
DextroamphetamineThe risk or severity of hypotension can be increased when Dextroamphetamine is combined with Methsuximide.Approved, Illicit
DextromoramideThe risk or severity of adverse effects can be increased when Methsuximide is combined with Dextromoramide.Experimental, Illicit
DextropropoxypheneThe risk or severity of adverse effects can be increased when Methsuximide is combined with Dextropropoxyphene.Approved, Illicit, Investigational, Withdrawn
DezocineThe risk or severity of adverse effects can be increased when Methsuximide is combined with Dezocine.Approved, Investigational
DiazepamThe risk or severity of adverse effects can be increased when Diazepam is combined with Methsuximide.Approved, Illicit, Investigational, Vet Approved
DichloropheneThe therapeutic efficacy of Dichlorophene can be increased when used in combination with Methsuximide.Vet Approved
Diethyl etherThe risk or severity of adverse effects can be increased when Methsuximide is combined with Diethyl ether.Experimental
DifenoxinThe risk or severity of adverse effects can be increased when Difenoxin is combined with Methsuximide.Approved, Illicit
DihydrocodeineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Methsuximide.Approved, Illicit
DihydroetorphineThe risk or severity of adverse effects can be increased when Methsuximide is combined with Dihydroetorphine.Experimental, Illicit
DihydromorphineThe risk or severity of adverse effects can be increased when Methsuximide is combined with Dihydromorphine.Experimental, Illicit
DimenhydrinateThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Methsuximide.Approved
DiphenhydramineThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Methsuximide.Approved, Investigational
DiphenoxylateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Methsuximide.Approved, Illicit
DixyrazineThe risk or severity of adverse effects can be increased when Methsuximide is combined with Dixyrazine.Experimental
DoramectinThe risk or severity of adverse effects can be increased when Methsuximide is combined with Doramectin.Vet Approved
DoxazosinThe risk or severity of hypotension can be increased when Doxazosin is combined with Methsuximide.Approved
DoxepinThe risk or severity of adverse effects can be increased when Doxepin is combined with Methsuximide.Approved, Investigational
DoxofyllineThe serum concentration of Doxofylline can be decreased when it is combined with Methsuximide.Approved, Investigational
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Methsuximide.Approved, Vet Approved
DPDPEThe risk or severity of adverse effects can be increased when Methsuximide is combined with DPDPE.Experimental
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Methsuximide.Approved, Illicit
DronedaroneThe risk or severity of hypotension can be increased when Dronedarone is combined with Methsuximide.Approved
DroperidolDroperidol may increase the central nervous system depressant (CNS depressant) activities of Methsuximide.Approved, Vet Approved
DrotebanolThe risk or severity of adverse effects can be increased when Methsuximide is combined with Drotebanol.Experimental, Illicit
DuloxetineThe risk or severity of adverse effects can be increased when Methsuximide is combined with Duloxetine.Approved
DyclonineThe risk or severity of adverse effects can be increased when Methsuximide is combined with Dyclonine.Approved
EcgonineThe risk or severity of adverse effects can be increased when Methsuximide is combined with Ecgonine.Experimental, Illicit
EconazoleThe therapeutic efficacy of Econazole can be increased when used in combination with Methsuximide.Approved
EcopipamThe risk or severity of adverse effects can be increased when Methsuximide is combined with Ecopipam.Investigational
EfavirenzThe serum concentration of Methsuximide can be decreased when it is combined with Efavirenz.Approved, Investigational
EfinaconazoleThe therapeutic efficacy of Efinaconazole can be increased when used in combination with Methsuximide.Approved
EltanoloneThe risk or severity of adverse effects can be increased when Methsuximide is combined with Eltanolone.Investigational
EnfluraneThe risk or severity of adverse effects can be increased when Methsuximide is combined with Enflurane.Approved, Investigational, Vet Approved
EntacaponeThe risk or severity of adverse effects can be increased when Entacapone is combined with Methsuximide.Approved, Investigational
EpinephrineThe risk or severity of hypotension can be increased when Epinephrine is combined with Methsuximide.Approved, Vet Approved
EscitalopramThe risk or severity of adverse effects can be increased when Methsuximide is combined with Escitalopram.Approved, Investigational
Eslicarbazepine acetateThe metabolism of Methsuximide can be decreased when combined with Eslicarbazepine acetate.Approved
EsomeprazoleThe metabolism of Methsuximide can be decreased when combined with Esomeprazole.Approved, Investigational
EstazolamThe risk or severity of adverse effects can be increased when Estazolam is combined with Methsuximide.Approved, Illicit
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Methsuximide.Approved, Investigational
EthanolMethsuximide may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved
EthchlorvynolThe risk or severity of adverse effects can be increased when Methsuximide is combined with Ethchlorvynol.Approved, Illicit, Withdrawn
EthosuximideThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Methsuximide.Approved
EthotoinThe risk or severity of adverse effects can be increased when Ethotoin is combined with Methsuximide.Approved
Ethyl carbamateThe risk or severity of adverse effects can be increased when Methsuximide is combined with Ethyl carbamate.Withdrawn
Ethyl chlorideThe risk or severity of adverse effects can be increased when Methsuximide is combined with Ethyl chloride.Approved, Experimental, Investigational
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Methsuximide is combined with Ethyl loflazepate.Approved, Illicit
EthylmorphineThe risk or severity of adverse effects can be increased when Methsuximide is combined with Ethylmorphine.Approved, Illicit
EtidocaineThe risk or severity of adverse effects can be increased when Methsuximide is combined with Etidocaine.Approved
EtifoxineThe risk or severity of adverse effects can be increased when Methsuximide is combined with Etifoxine.Investigational, Withdrawn
EtizolamThe risk or severity of adverse effects can be increased when Methsuximide is combined with Etizolam.Approved
EtomidateThe risk or severity of adverse effects can be increased when Methsuximide is combined with Etomidate.Approved
EtoperidoneThe risk or severity of adverse effects can be increased when Methsuximide is combined with Etoperidone.Withdrawn
EtorphineThe risk or severity of adverse effects can be increased when Methsuximide is combined with Etorphine.Illicit, Vet Approved
EtravirineThe metabolism of Methsuximide can be decreased when combined with Etravirine.Approved
EzogabineThe risk or severity of adverse effects can be increased when Ezogabine is combined with Methsuximide.Approved, Investigational
FelbamateThe risk or severity of adverse effects can be increased when Felbamate is combined with Methsuximide.Approved
FencamfamineThe risk or severity of adverse effects can be increased when Methsuximide is combined with Fencamfamine.Approved, Illicit, Withdrawn
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Methsuximide.Approved, Illicit, Investigational, Vet Approved
FenticonazoleThe therapeutic efficacy of Fenticonazole can be increased when used in combination with Methsuximide.Experimental
FexofenadineThe risk or severity of adverse effects can be increased when Fexofenadine is combined with Methsuximide.Approved, Investigational
FlibanserinThe risk or severity of adverse effects can be increased when Flibanserin is combined with Methsuximide.Approved, Investigational
FluanisoneThe risk or severity of adverse effects can be increased when Methsuximide is combined with Fluanisone.Experimental
FluconazoleThe metabolism of Methsuximide can be decreased when combined with Fluconazole.Approved, Investigational
FlucytosineThe therapeutic efficacy of Flucytosine can be increased when used in combination with Methsuximide.Approved, Investigational
FludiazepamThe risk or severity of adverse effects can be increased when Methsuximide is combined with Fludiazepam.Approved, Illicit
FlunarizineThe risk or severity of adverse effects can be increased when Flunarizine is combined with Methsuximide.Approved
FlunitrazepamThe risk or severity of adverse effects can be increased when Methsuximide is combined with Flunitrazepam.Approved, Illicit
FluoxetineThe metabolism of Methsuximide can be decreased when combined with Fluoxetine.Approved, Vet Approved
FlupentixolThe risk or severity of adverse effects can be increased when Flupentixol is combined with Methsuximide.Approved, Investigational, Withdrawn
FluphenazineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Methsuximide.Approved
FlurazepamThe risk or severity of adverse effects can be increased when Flurazepam is combined with Methsuximide.Approved, Illicit, Investigational
FluspirileneThe risk or severity of adverse effects can be increased when Methsuximide is combined with Fluspirilene.Approved, Investigational
Fluticasone propionateThe risk or severity of adverse effects can be increased when Fluticasone propionate is combined with Methsuximide.Approved
FlutrimazoleThe therapeutic efficacy of Flutrimazole can be increased when used in combination with Methsuximide.Experimental
FluvoxamineThe metabolism of Methsuximide can be decreased when combined with Fluvoxamine.Approved, Investigational
FosphenytoinThe metabolism of Methsuximide can be increased when combined with Fosphenytoin.Approved, Investigational
FospropofolThe risk or severity of adverse effects can be increased when Methsuximide is combined with Fospropofol.Approved, Illicit, Investigational
GabapentinThe risk or severity of adverse effects can be increased when Gabapentin is combined with Methsuximide.Approved, Investigational
Gabapentin EnacarbilThe risk or severity of adverse effects can be increased when Methsuximide is combined with Gabapentin Enacarbil.Approved, Investigational
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Gamma Hydroxybutyric Acid is combined with Methsuximide.Approved, Illicit, Investigational
GemfibrozilThe metabolism of Methsuximide can be decreased when combined with Gemfibrozil.Approved
GepironeThe risk or severity of adverse effects can be increased when Methsuximide is combined with Gepirone.Investigational
GlutethimideThe risk or severity of adverse effects can be increased when Methsuximide is combined with Glutethimide.Approved, Illicit
GlyphosateThe therapeutic efficacy of Glyphosate can be increased when used in combination with Methsuximide.Experimental
GriseofulvinThe therapeutic efficacy of Griseofulvin can be increased when used in combination with Methsuximide.Approved, Investigational, Vet Approved
GuanfacineThe risk or severity of adverse effects can be increased when Guanfacine is combined with Methsuximide.Approved, Investigational
HachimycinThe therapeutic efficacy of Hachimycin can be increased when used in combination with Methsuximide.Experimental
HalazepamThe risk or severity of adverse effects can be increased when Methsuximide is combined with Halazepam.Approved, Illicit, Withdrawn
HaloperidolThe risk or severity of adverse effects can be increased when Haloperidol is combined with Methsuximide.Approved
HaloproginThe therapeutic efficacy of Haloprogin can be increased when used in combination with Methsuximide.Approved, Withdrawn
HalothaneThe risk or severity of adverse effects can be increased when Methsuximide is combined with Halothane.Approved, Vet Approved
HeroinThe risk or severity of adverse effects can be increased when Methsuximide is combined with Heroin.Approved, Illicit, Investigational
HexetidineThe therapeutic efficacy of Hexetidine can be increased when used in combination with Methsuximide.Approved, Investigational
HexobarbitalThe risk or severity of adverse effects can be increased when Methsuximide is combined with Hexobarbital.Approved
HydrocodoneMethsuximide may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Methsuximide.Approved, Illicit
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Methsuximide.Approved
IloperidoneThe risk or severity of adverse effects can be increased when Iloperidone is combined with Methsuximide.Approved
ImipramineThe risk or severity of adverse effects can be increased when Imipramine is combined with Methsuximide.Approved
IndalpineThe risk or severity of adverse effects can be increased when Methsuximide is combined with Indalpine.Investigational, Withdrawn
IndinavirThe metabolism of Methsuximide can be decreased when combined with Indinavir.Approved
IndiplonThe risk or severity of adverse effects can be increased when Methsuximide is combined with Indiplon.Investigational
IndoraminThe risk or severity of hypotension can be increased when Indoramin is combined with Methsuximide.Withdrawn
IsoconazoleThe therapeutic efficacy of Isoconazole can be increased when used in combination with Methsuximide.Approved
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Methsuximide.Approved, Vet Approved
IsoniazidThe metabolism of Methsuximide can be decreased when combined with Isoniazid.Approved, Investigational
ItraconazoleThe therapeutic efficacy of Itraconazole can be increased when used in combination with Methsuximide.Approved, Investigational
KetamineThe risk or severity of adverse effects can be increased when Ketamine is combined with Methsuximide.Approved, Vet Approved
KetazolamThe risk or severity of adverse effects can be increased when Methsuximide is combined with Ketazolam.Approved
KetobemidoneThe risk or severity of adverse effects can be increased when Methsuximide is combined with Ketobemidone.Approved, Investigational
KetoconazoleThe metabolism of Methsuximide can be decreased when combined with Ketoconazole.Approved, Investigational
LabetalolThe risk or severity of hypotension can be increased when Labetalol is combined with Methsuximide.Approved
LamotrigineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Methsuximide.Approved, Investigational
LevetiracetamThe risk or severity of adverse effects can be increased when Levetiracetam is combined with Methsuximide.Approved, Investigational
LevobupivacaineThe risk or severity of adverse effects can be increased when Methsuximide is combined with Levobupivacaine.Approved, Investigational
LevocabastineThe risk or severity of adverse effects can be increased when Methsuximide is combined with Levocabastine.Approved, Investigational
LevocetirizineThe risk or severity of adverse effects can be increased when Methsuximide is combined with Levocetirizine.Approved
LevodopaThe risk or severity of adverse effects can be increased when Levodopa is combined with Methsuximide.Approved
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Methsuximide is combined with Levomethadyl Acetate.Approved, Investigational
LevomilnacipranThe risk or severity of adverse effects can be increased when Methsuximide is combined with Levomilnacipran.Approved, Investigational
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Methsuximide.Approved
LidocaineThe risk or severity of adverse effects can be increased when Methsuximide is combined with Lidocaine.Approved, Vet Approved
LisdexamfetamineThe risk or severity of hypotension can be increased when Lisdexamfetamine is combined with Methsuximide.Approved, Investigational
LithiumThe risk or severity of adverse effects can be increased when Methsuximide is combined with Lithium.Approved
LobeglitazoneThe metabolism of Methsuximide can be decreased when combined with Lobeglitazone.Approved, Investigational
LofentanilThe risk or severity of adverse effects can be increased when Methsuximide is combined with Lofentanil.Illicit
LofexidineThe therapeutic efficacy of Methsuximide can be increased when used in combination with Lofexidine.Approved, Investigational
LopinavirThe metabolism of Methsuximide can be increased when combined with Lopinavir.Approved
LoprazolamThe risk or severity of adverse effects can be increased when Methsuximide is combined with Loprazolam.Experimental
LoratadineThe risk or severity of adverse effects can be increased when Loratadine is combined with Methsuximide.Approved, Investigational
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Methsuximide.Approved
LormetazepamThe risk or severity of adverse effects can be increased when Methsuximide is combined with Lormetazepam.Approved
LoxapineThe risk or severity of adverse effects can be increased when Loxapine is combined with Methsuximide.Approved
LuliconazoleThe serum concentration of Methsuximide can be increased when it is combined with Luliconazole.Approved
LumacaftorThe serum concentration of Methsuximide can be decreased when it is combined with Lumacaftor.Approved
LurasidoneThe risk or severity of adverse effects can be increased when Lurasidone is combined with Methsuximide.Approved, Investigational
Magnesium hydroxideThe risk or severity of hypotension and neuromuscular blockade can be increased when Methsuximide is combined with Magnesium hydroxide.Approved, Investigational
Magnesium oxideThe risk or severity of hypotension and neuromuscular blockade can be increased when Methsuximide is combined with Magnesium oxide.Approved
Magnesium salicylateThe risk or severity of hypotension and neuromuscular blockade can be increased when Methsuximide is combined with Magnesium salicylate.Approved
Magnesium sulfateThe therapeutic efficacy of Methsuximide can be increased when used in combination with Magnesium sulfate.Approved, Investigational, Vet Approved
MaprotilineThe risk or severity of adverse effects can be increased when Maprotiline is combined with Methsuximide.Approved, Investigational
MebicarThe risk or severity of adverse effects can be increased when Methsuximide is combined with Mebicar.Experimental
MeclizineThe risk or severity of adverse effects can be increased when Meclizine is combined with Methsuximide.Approved
MedazepamThe risk or severity of adverse effects can be increased when Methsuximide is combined with Medazepam.Experimental
MedetomidineThe risk or severity of adverse effects can be increased when Methsuximide is combined with Medetomidine.Vet Approved
MefloquineThe therapeutic efficacy of Methsuximide can be decreased when used in combination with Mefloquine.Approved, Investigational
MelatoninThe risk or severity of adverse effects can be increased when Methsuximide is combined with Melatonin.Approved, Nutraceutical, Vet Approved
MelperoneThe risk or severity of adverse effects can be increased when Methsuximide is combined with Melperone.Approved, Investigational
MepartricinThe therapeutic efficacy of Mepartricin can be increased when used in combination with Methsuximide.Experimental
MepivacaineThe risk or severity of adverse effects can be increased when Methsuximide is combined with Mepivacaine.Approved, Vet Approved
MeprobamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Methsuximide.Approved, Illicit
MeptazinolThe risk or severity of adverse effects can be increased when Methsuximide is combined with Meptazinol.Experimental
MesoridazineThe risk or severity of adverse effects can be increased when Methsuximide is combined with Mesoridazine.Approved, Investigational
MetaxaloneThe risk or severity of adverse effects can be increased when Metaxalone is combined with Methsuximide.Approved
MethadoneThe risk or severity of adverse effects can be increased when Methadone is combined with Methsuximide.Approved
Methadyl AcetateThe risk or severity of adverse effects can be increased when Methsuximide is combined with Methadyl Acetate.Approved, Illicit
MethapyrileneThe risk or severity of adverse effects can be increased when Methsuximide is combined with Methapyrilene.Withdrawn
MethaqualoneThe risk or severity of adverse effects can be increased when Methsuximide is combined with Methaqualone.Illicit, Withdrawn
MethocarbamolThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Methsuximide.Approved, Vet Approved
MethohexitalThe risk or severity of adverse effects can be increased when Methohexital is combined with Methsuximide.Approved
MethotrimeprazineMethsuximide may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved, Investigational
MethoxyfluraneThe risk or severity of adverse effects can be increased when Methsuximide is combined with Methoxyflurane.Approved, Investigational, Vet Approved
MethylecgonineThe risk or severity of adverse effects can be increased when Methsuximide is combined with Methylecgonine.Experimental
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Methsuximide is combined with Methylphenobarbital.Approved
MetyrosineMethsuximide may increase the sedative activities of Metyrosine.Approved
MevastatinThe therapeutic efficacy of Mevastatin can be increased when used in combination with Methsuximide.Experimental
MianserinThe therapeutic efficacy of Methsuximide can be decreased when used in combination with Mianserin.Approved, Investigational
MicafunginThe therapeutic efficacy of Micafungin can be increased when used in combination with Methsuximide.Approved, Investigational
MiconazoleThe therapeutic efficacy of Miconazole can be increased when used in combination with Methsuximide.Approved, Investigational, Vet Approved
MidazolamThe risk or severity of adverse effects can be increased when Midazolam is combined with Methsuximide.Approved, Illicit
MilnacipranThe risk or severity of adverse effects can be increased when Methsuximide is combined with Milnacipran.Approved, Investigational
MiltefosineThe therapeutic efficacy of Miltefosine can be increased when used in combination with Methsuximide.Approved, Investigational
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Methsuximide.Approved, Investigational
MirtazapineMethsuximide may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved
MoclobemideThe metabolism of Methsuximide can be decreased when combined with Moclobemide.Approved, Investigational
ModafinilThe metabolism of Methsuximide can be decreased when combined with Modafinil.Approved, Investigational
MolindoneThe risk or severity of adverse effects can be increased when Methsuximide is combined with Molindone.Approved
MonensinThe therapeutic efficacy of Monensin can be increased when used in combination with Methsuximide.Vet Approved
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Methsuximide.Approved, Investigational
MyxothiazolThe therapeutic efficacy of Myxothiazol can be increased when used in combination with Methsuximide.Experimental
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Methsuximide.Approved, Investigational
NafcillinThe therapeutic efficacy of Methsuximide can be decreased when used in combination with Nafcillin.Approved, Investigational
NaftifineThe therapeutic efficacy of Naftifine can be increased when used in combination with Methsuximide.Approved
NalbuphineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Methsuximide.Approved
NatamycinThe therapeutic efficacy of Natamycin can be increased when used in combination with Methsuximide.Approved
NefazodoneThe risk or severity of adverse effects can be increased when Methsuximide is combined with Nefazodone.Approved, Withdrawn
NelfinavirThe metabolism of Methsuximide can be decreased when combined with Nelfinavir.Approved
NicardipineThe metabolism of Methsuximide can be decreased when combined with Nicardipine.Approved, Investigational
NicergolineThe risk or severity of hypotension can be increased when Nicergoline is combined with Methsuximide.Approved, Investigational
NifuratelThe therapeutic efficacy of Nifuratel can be increased when used in combination with Methsuximide.Experimental
NiguldipineThe risk or severity of hypotension can be increased when Niguldipine is combined with Methsuximide.Experimental
Nikkomycin ZThe therapeutic efficacy of Nikkomycin Z can be increased when used in combination with Methsuximide.Investigational
NitrazepamThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Methsuximide.Approved
NitroprussideMethsuximide may increase the hypotensive activities of Nitroprusside.Approved, Investigational
Nitrous oxideThe risk or severity of adverse effects can be increased when Nitrous oxide is combined with Methsuximide.Approved, Vet Approved
NitroxolineThe therapeutic efficacy of Nitroxoline can be increased when used in combination with Methsuximide.Approved
NordazepamThe risk or severity of adverse effects can be increased when Methsuximide is combined with Nordazepam.Approved
NorfluraneThe risk or severity of adverse effects can be increased when Methsuximide is combined with Norflurane.Approved, Investigational
NormethadoneThe risk or severity of adverse effects can be increased when Methsuximide is combined with Normethadone.Approved, Illicit
NortriptylineThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Methsuximide.Approved
NystatinThe therapeutic efficacy of Nystatin can be increased when used in combination with Methsuximide.Approved, Vet Approved
OlanzapineThe risk or severity of adverse effects can be increased when Olanzapine is combined with Methsuximide.Approved, Investigational
OlopatadineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Methsuximide.Approved
OmeprazoleThe metabolism of Methsuximide can be decreased when combined with Omeprazole.Approved, Investigational, Vet Approved
OmoconazoleThe therapeutic efficacy of Omoconazole can be increased when used in combination with Methsuximide.Experimental
OndansetronThe risk or severity of adverse effects can be increased when Methsuximide is combined with Ondansetron.Approved
OpiumThe risk or severity of adverse effects can be increased when Methsuximide is combined with Opium.Approved, Illicit
OrlistatThe serum concentration of Methsuximide can be decreased when it is combined with Orlistat.Approved, Investigational
OrphenadrineMethsuximide may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
OsanetantThe risk or severity of adverse effects can be increased when Methsuximide is combined with Osanetant.Investigational
OxazepamThe risk or severity of adverse effects can be increased when Oxazepam is combined with Methsuximide.Approved
OxiconazoleThe therapeutic efficacy of Oxiconazole can be increased when used in combination with Methsuximide.Approved
OxprenololThe risk or severity of adverse effects can be increased when Methsuximide is combined with Oxprenolol.Approved
OxybuprocaineThe risk or severity of adverse effects can be increased when Methsuximide is combined with Oxybuprocaine.Approved, Investigational
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Methsuximide.Approved, Illicit, Investigational
OxymorphoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Methsuximide.Approved, Investigational, Vet Approved
PafuramidineThe therapeutic efficacy of Pafuramidine can be increased when used in combination with Methsuximide.Investigational
PaliperidoneThe risk or severity of adverse effects can be increased when Paliperidone is combined with Methsuximide.Approved
PantoprazoleThe metabolism of Methsuximide can be decreased when combined with Pantoprazole.Approved
ParaldehydeMethsuximide may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.Approved, Investigational
ParoxetineThe risk or severity of adverse effects can be increased when Methsuximide is combined with Paroxetine.Approved, Investigational
PenfluridolThe risk or severity of adverse effects can be increased when Methsuximide is combined with Penfluridol.Experimental
PentamidineThe therapeutic efficacy of Pentamidine can be increased when used in combination with Methsuximide.Approved, Investigational
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Methsuximide.Approved, Vet Approved
PentobarbitalThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Methsuximide.Approved, Investigational, Vet Approved
PerampanelPerampanel may increase the central nervous system depressant (CNS depressant) activities of Methsuximide.Approved
PerazineThe risk or severity of adverse effects can be increased when Methsuximide is combined with Perazine.Approved, Investigational
PerospironeThe risk or severity of adverse effects can be increased when Methsuximide is combined with Perospirone.Approved
PerphenazineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Methsuximide.Approved
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Methsuximide.Approved
PhenazocineThe risk or severity of adverse effects can be increased when Methsuximide is combined with Phenazocine.Experimental
PhenibutThe risk or severity of adverse effects can be increased when Methsuximide is combined with Phenibut.Experimental
PhenobarbitalThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Methsuximide.Approved, Investigational
PhenoperidineThe risk or severity of adverse effects can be increased when Methsuximide is combined with Phenoperidine.Experimental
PhenoxybenzamineThe risk or severity of hypotension can be increased when Phenoxybenzamine is combined with Methsuximide.Approved
PhenoxyethanolThe risk or severity of adverse effects can be increased when Methsuximide is combined with Phenoxyethanol.Approved
PhentolamineThe risk or severity of hypotension can be increased when Phentolamine is combined with Methsuximide.Approved
PhenytoinThe metabolism of Methsuximide can be increased when combined with Phenytoin.Approved, Vet Approved
PimozideThe risk or severity of adverse effects can be increased when Pimozide is combined with Methsuximide.Approved
PipamperoneThe risk or severity of adverse effects can be increased when Methsuximide is combined with Pipamperone.Approved, Investigational
PipotiazineThe risk or severity of adverse effects can be increased when Pipotiazine is combined with Methsuximide.Approved, Investigational
PiritramideThe risk or severity of adverse effects can be increased when Methsuximide is combined with Piritramide.Approved, Investigational
PizotifenThe risk or severity of adverse effects can be increased when Methsuximide is combined with Pizotifen.Approved
PomalidomideThe risk or severity of adverse effects can be increased when Methsuximide is combined with Pomalidomide.Approved
PosaconazoleThe therapeutic efficacy of Posaconazole can be increased when used in combination with Methsuximide.Approved, Investigational, Vet Approved
PramipexoleMethsuximide may increase the sedative activities of Pramipexole.Approved, Investigational
PramocaineThe risk or severity of adverse effects can be increased when Methsuximide is combined with Pramocaine.Approved
PrazepamThe risk or severity of adverse effects can be increased when Methsuximide is combined with Prazepam.Approved, Illicit
PrazosinThe risk or severity of hypotension can be increased when Prazosin is combined with Methsuximide.Approved
PregabalinThe therapeutic efficacy of Methsuximide can be decreased when used in combination with Pregabalin.Approved, Illicit, Investigational
PrilocaineThe risk or severity of adverse effects can be increased when Methsuximide is combined with Prilocaine.Approved
PrimidoneThe risk or severity of adverse effects can be increased when Primidone is combined with Methsuximide.Approved, Vet Approved
ProcaineThe risk or severity of adverse effects can be increased when Methsuximide is combined with Procaine.Approved, Investigational, Vet Approved
ProchlorperazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Methsuximide.Approved, Vet Approved
PromazineThe risk or severity of adverse effects can be increased when Promazine is combined with Methsuximide.Approved, Vet Approved
PromethazineThe risk or severity of adverse effects can be increased when Promethazine is combined with Methsuximide.Approved, Investigational
PropanididThe risk or severity of adverse effects can be increased when Methsuximide is combined with Propanidid.Experimental
ProparacaineThe risk or severity of adverse effects can be increased when Methsuximide is combined with Proparacaine.Approved, Vet Approved
PropericiazineThe risk or severity of hypotension can be increased when Propericiazine is combined with Methsuximide.Approved, Investigational
PropiomazineThe risk or severity of hypotension can be increased when Propiomazine is combined with Methsuximide.Approved
PropiverineThe risk or severity of hypotension can be increased when Propiverine is combined with Methsuximide.Approved, Investigational
PropofolThe risk or severity of adverse effects can be increased when Propofol is combined with Methsuximide.Approved, Investigational, Vet Approved
PropoxycaineThe risk or severity of adverse effects can be increased when Methsuximide is combined with Propoxycaine.Approved
ProtriptylineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Methsuximide.Approved
ProxibarbalThe risk or severity of adverse effects can be increased when Methsuximide is combined with Proxibarbal.Experimental
PSD502The risk or severity of adverse effects can be increased when Methsuximide is combined with PSD502.Investigational
PyrrolnitrinThe therapeutic efficacy of Pyrrolnitrin can be increased when used in combination with Methsuximide.Experimental
QuazepamThe risk or severity of adverse effects can be increased when Quazepam is combined with Methsuximide.Approved, Illicit
QuetiapineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Methsuximide.Approved
QuinidineThe risk or severity of hypotension can be increased when Quinidine is combined with Methsuximide.Approved, Investigational
QuinisocaineThe risk or severity of adverse effects can be increased when Methsuximide is combined with Quinisocaine.Experimental
RacepinephrineThe risk or severity of hypotension can be increased when Racepinephrine is combined with Methsuximide.Approved
RacloprideThe risk or severity of adverse effects can be increased when Methsuximide is combined with Raclopride.Investigational
RadicicolThe therapeutic efficacy of Radicicol can be increased when used in combination with Methsuximide.Experimental
RamelteonThe risk or severity of adverse effects can be increased when Ramelteon is combined with Methsuximide.Approved, Investigational
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Methsuximide.Approved
RemoxiprideThe risk or severity of adverse effects can be increased when Methsuximide is combined with Remoxipride.Approved, Withdrawn
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Methsuximide.Approved, Investigational
RifabutinThe risk or severity of hypotension can be increased when Rifabutin is combined with Methsuximide.Approved, Investigational
RifampicinThe metabolism of Methsuximide can be increased when combined with Rifampicin.Approved
RifapentineThe risk or severity of hypotension can be increased when Rifapentine is combined with Methsuximide.Approved, Investigational
RifaximinThe risk or severity of hypotension can be increased when Rifaximin is combined with Methsuximide.Approved, Investigational
RisperidoneThe risk or severity of adverse effects can be increased when Risperidone is combined with Methsuximide.Approved, Investigational
RitanserinThe risk or severity of adverse effects can be increased when Methsuximide is combined with Ritanserin.Investigational
RomifidineThe risk or severity of adverse effects can be increased when Methsuximide is combined with Romifidine.Vet Approved
RopiniroleMethsuximide may increase the sedative activities of Ropinirole.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Methsuximide is combined with Ropivacaine.Approved
RotigotineMethsuximide may increase the sedative activities of Rotigotine.Approved
RucaparibThe metabolism of Methsuximide can be decreased when combined with Rucaparib.Approved, Investigational
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Methsuximide.Approved
Salicylhydroxamic AcidThe therapeutic efficacy of Salicylhydroxamic Acid can be increased when used in combination with Methsuximide.Experimental
Salicylic acidThe therapeutic efficacy of Salicylic acid can be increased when used in combination with Methsuximide.Approved, Investigational, Vet Approved
ScopolamineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Methsuximide.Approved, Investigational
SecobarbitalThe risk or severity of adverse effects can be increased when Secobarbital is combined with Methsuximide.Approved, Vet Approved
SepranoloneThe risk or severity of adverse effects can be increased when Methsuximide is combined with Sepranolone.Investigational
SertaconazoleThe therapeutic efficacy of Sertaconazole can be increased when used in combination with Methsuximide.Approved, Investigational
SertindoleThe risk or severity of adverse effects can be increased when Methsuximide is combined with Sertindole.Approved, Investigational, Withdrawn
SertralineThe metabolism of Methsuximide can be decreased when combined with Sertraline.Approved
SevofluraneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Methsuximide.Approved, Vet Approved
SilodosinThe risk or severity of hypotension can be increased when Silodosin is combined with Methsuximide.Approved
SinefunginThe therapeutic efficacy of Sinefungin can be increased when used in combination with Methsuximide.Experimental
SirolimusThe therapeutic efficacy of Sirolimus can be increased when used in combination with Methsuximide.Approved, Investigational
Sodium oxybateSodium oxybate may increase the central nervous system depressant (CNS depressant) activities of Methsuximide.Approved
StiripentolThe metabolism of Methsuximide can be decreased when combined with Stiripentol.Approved
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Methsuximide.Approved, Investigational
SulconazoleThe therapeutic efficacy of Sulconazole can be increased when used in combination with Methsuximide.Approved
SulpirideThe risk or severity of adverse effects can be increased when Methsuximide is combined with Sulpiride.Approved, Investigational
SultoprideThe risk or severity of adverse effects can be increased when Methsuximide is combined with Sultopride.Experimental
SuvorexantMethsuximide may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved, Investigational
TamsulosinThe risk or severity of hypotension can be increased when Tamsulosin is combined with Methsuximide.Approved, Investigational
TandospironeThe risk or severity of adverse effects can be increased when Methsuximide is combined with Tandospirone.Investigational
TapentadolTapentadol may increase the central nervous system depressant (CNS depressant) activities of Methsuximide.Approved
TasimelteonThe risk or severity of adverse effects can be increased when Methsuximide is combined with Tasimelteon.Approved, Investigational
TavaboroleThe therapeutic efficacy of Tavaborole can be increased when used in combination with Methsuximide.Approved, Investigational
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Methsuximide.Approved, Investigational
TerazosinThe risk or severity of hypotension can be increased when Terazosin is combined with Methsuximide.Approved
TerbinafineThe therapeutic efficacy of Terbinafine can be increased when used in combination with Methsuximide.Approved, Investigational, Vet Approved
TerconazoleThe therapeutic efficacy of Terconazole can be increased when used in combination with Methsuximide.Approved
TetrabenazineThe risk or severity of adverse effects can be increased when Tetrabenazine is combined with Methsuximide.Approved, Investigational
TetracaineThe risk or severity of adverse effects can be increased when Methsuximide is combined with Tetracaine.Approved, Vet Approved
TetrahydropalmatineThe risk or severity of adverse effects can be increased when Methsuximide is combined with Tetrahydropalmatine.Investigational
TetrodotoxinThe risk or severity of adverse effects can be increased when Methsuximide is combined with Tetrodotoxin.Investigational
ThalidomideMethsuximide may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved, Investigational, Withdrawn
ThiamylalThe risk or severity of adverse effects can be increased when Methsuximide is combined with Thiamylal.Approved, Vet Approved
ThiopentalThe risk or severity of adverse effects can be increased when Methsuximide is combined with Thiopental.Approved, Vet Approved
ThioproperazineThe risk or severity of hypotension can be increased when Thioproperazine is combined with Methsuximide.Approved
ThioridazineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Methsuximide.Approved, Withdrawn
ThiothixeneThe risk or severity of adverse effects can be increased when Thiothixene is combined with Methsuximide.Approved
ThymolThe therapeutic efficacy of Thymol can be increased when used in combination with Methsuximide.Approved
TiagabineThe risk or severity of adverse effects can be increased when Tiagabine is combined with Methsuximide.Approved, Investigational
TiaprideThe risk or severity of adverse effects can be increased when Methsuximide is combined with Tiapride.Approved, Investigational
TiclopidineThe metabolism of Methsuximide can be decreased when combined with Ticlopidine.Approved
TiletamineThe risk or severity of adverse effects can be increased when Methsuximide is combined with Tiletamine.Vet Approved
TilidineThe risk or severity of adverse effects can be increased when Methsuximide is combined with Tilidine.Experimental
TioconazoleThe therapeutic efficacy of Tioconazole can be increased when used in combination with Methsuximide.Approved
TizanidineThe risk or severity of adverse effects can be increased when Tizanidine is combined with Methsuximide.Approved, Investigational
TolazolineThe risk or severity of hypotension can be increased when Tolazoline is combined with Methsuximide.Approved, Vet Approved
TolcaponeThe risk or severity of adverse effects can be increased when Tolcapone is combined with Methsuximide.Approved, Withdrawn
TolciclateThe therapeutic efficacy of Tolciclate can be increased when used in combination with Methsuximide.Experimental
TolnaftateThe therapeutic efficacy of Tolnaftate can be increased when used in combination with Methsuximide.Approved, Investigational, Vet Approved
TopiramateThe metabolism of Methsuximide can be decreased when combined with Topiramate.Approved
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Methsuximide.Approved, Investigational
TranylcypromineThe metabolism of Methsuximide can be decreased when combined with Tranylcypromine.Approved, Investigational
TrazodoneThe risk or severity of adverse effects can be increased when Methsuximide is combined with Trazodone.Approved, Investigational
TriazolamThe risk or severity of adverse effects can be increased when Triazolam is combined with Methsuximide.Approved, Investigational
Tricaine methanesulfonateThe risk or severity of adverse effects can be increased when Methsuximide is combined with Tricaine methanesulfonate.Vet Approved
TrichloroethyleneThe risk or severity of adverse effects can be increased when Methsuximide is combined with Trichloroethylene.Approved
TrifluoperazineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Methsuximide.Approved, Investigational
TrifluperidolThe risk or severity of adverse effects can be increased when Methsuximide is combined with Trifluperidol.Experimental
TriflupromazineThe risk or severity of adverse effects can be increased when Methsuximide is combined with Triflupromazine.Approved, Vet Approved
TrimazosinThe risk or severity of hypotension can be increased when Trimazosin is combined with Methsuximide.Experimental
TrimetrexateThe therapeutic efficacy of Trimetrexate can be increased when used in combination with Methsuximide.Approved, Investigational
TrimipramineThe risk or severity of adverse effects can be increased when Trimipramine is combined with Methsuximide.Approved
TriprolidineThe risk or severity of adverse effects can be increased when Triprolidine is combined with Methsuximide.Approved
UrapidilThe risk or severity of hypotension can be increased when Urapidil is combined with Methsuximide.Investigational
Valproic AcidThe risk or severity of adverse effects can be increased when Methsuximide is combined with Valproic Acid.Approved, Investigational
VenlafaxineThe risk or severity of adverse effects can be increased when Methsuximide is combined with Venlafaxine.Approved
VeraliprideThe risk or severity of adverse effects can be increased when Methsuximide is combined with Veralipride.Experimental
VerapamilThe risk or severity of hypotension can be increased when Verapamil is combined with Methsuximide.Approved
VigabatrinThe risk or severity of adverse effects can be increased when Vigabatrin is combined with Methsuximide.Approved
Vinyl etherThe risk or severity of adverse effects can be increased when Methsuximide is combined with Vinyl ether.Experimental
VoriconazoleThe metabolism of Methsuximide can be decreased when combined with Voriconazole.Approved, Investigational
VortioxetineThe risk or severity of adverse effects can be increased when Methsuximide is combined with Vortioxetine.Approved, Investigational
WortmanninThe therapeutic efficacy of Wortmannin can be increased when used in combination with Methsuximide.Experimental
XenonThe risk or severity of adverse effects can be increased when Methsuximide is combined with Xenon.Experimental
XylazineThe risk or severity of adverse effects can be increased when Methsuximide is combined with Xylazine.Vet Approved
ZaleplonThe risk or severity of adverse effects can be increased when Zaleplon is combined with Methsuximide.Approved, Illicit, Investigational
ZiconotideThe risk or severity of adverse effects can be increased when Methsuximide is combined with Ziconotide.Approved
ZimelidineThe risk or severity of adverse effects can be increased when Methsuximide is combined with Zimelidine.Withdrawn
ZiprasidoneThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Methsuximide.Approved
ZolazepamThe risk or severity of adverse effects can be increased when Methsuximide is combined with Zolazepam.Vet Approved
ZolpidemMethsuximide may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
ZonisamideThe risk or severity of adverse effects can be increased when Zonisamide is combined with Methsuximide.Approved, Investigational
ZopicloneThe risk or severity of adverse effects can be increased when Zopiclone is combined with Methsuximide.Approved
ZotepineThe risk or severity of adverse effects can be increased when Methsuximide is combined with Zotepine.Approved, Investigational, Withdrawn
ZucapsaicinThe metabolism of Methsuximide can be decreased when combined with Zucapsaicin.Approved, Investigational
ZuclopenthixolThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Methsuximide.Approved, Investigational
Food Interactions
  • Avoid alcohol
  • Take with food

References

General References
  1. Hurst DL: Methsuximide therapy of juvenile myoclonic epilepsy. Seizure. 1996 Mar;5(1):47-50. [PubMed:8777552]
  2. Besag FM, Berry DJ, Pool F: Methsuximide lowers lamotrigine blood levels: A pharmacokinetic antiepileptic drug interaction. Epilepsia. 2000 May;41(5):624-7. [PubMed:10802770]
External Links
Human Metabolome Database
HMDB0015611
PubChem Compound
6476
PubChem Substance
46505339
ChemSpider
6231
ChEBI
6846
ChEMBL
CHEMBL697
Therapeutic Targets Database
DAP001253
PharmGKB
PA164743145
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
Wikipedia
Methsuximide
ATC Codes
N03AD03 — Mesuximide

Clinical Trials

Clinical Trials
Not Available

Pharmacoeconomics

Manufacturers
Not Available
Packagers
  • Farmea
  • Kaiser Foundation Hospital
  • Pfizer Inc.
Dosage forms
FormRouteStrength
CapsuleOral300 mg/1
CapsuleOral300 mg
Prices
Unit descriptionCostUnit
Celontin 300 mg kapseal1.53USD each
Celontin 300 mg Capsule1.1USD capsule
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)52.5 °CPhysProp
boiling point (°C)121.5 °C at 1.00E-01 mm HgPhysProp
Predicted Properties
PropertyValueSource
Water Solubility2.13 mg/mLALOGPS
logP1.46ALOGPS
logP1.46ChemAxon
logS-2ALOGPS
pKa (Strongest Acidic)19.03ChemAxon
pKa (Strongest Basic)-7.2ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count2ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area37.38 Å2ChemAxon
Rotatable Bond Count1ChemAxon
Refractivity56.35 m3·mol-1ChemAxon
Polarizability21.4 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+1.0
Blood Brain Barrier+0.9967
Caco-2 permeable+0.6968
P-glycoprotein substrateNon-substrate0.7118
P-glycoprotein inhibitor INon-inhibitor0.8599
P-glycoprotein inhibitor IINon-inhibitor0.9433
Renal organic cation transporterNon-inhibitor0.7784
CYP450 2C9 substrateNon-substrate0.7943
CYP450 2D6 substrateNon-substrate0.8923
CYP450 3A4 substrateSubstrate0.6004
CYP450 1A2 substrateNon-inhibitor0.888
CYP450 2C9 inhibitorNon-inhibitor0.8882
CYP450 2D6 inhibitorNon-inhibitor0.922
CYP450 2C19 inhibitorNon-inhibitor0.845
CYP450 3A4 inhibitorNon-inhibitor0.9748
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9629
Ames testNon AMES toxic0.9099
CarcinogenicityNon-carcinogens0.8355
BiodegradationNot ready biodegradable0.8265
Rat acute toxicity2.1961 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9942
hERG inhibition (predictor II)Non-inhibitor0.9625
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
GC-MS Spectrum - EI-BGC-MSsplash10-014i-3910000000-9cae394b5b94a483c401
GC-MS Spectrum - CI-BGC-MSsplash10-0udi-0090000000-31b6e0b0429306f0d6da
GC-MS Spectrum - CI-BGC-MSsplash10-0udi-0490000000-37eb2b7cfbb3d8b42e97
Mass Spectrum (Electron Ionization)MSsplash10-014i-4910000000-aa3742fc04cdbcda351f
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-0udi-0390000000-00d729cf9e85b7d75068
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-0udi-1690000000-0a263ad37a0831b81fb3
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-014i-4910000000-eb0a383017c0566e6a11
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-014l-9800000000-5df2aae06682d9488eef
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-05mo-9400000000-6de622fc3efce00a0b34
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-052f-9300000000-1e2faae8b516a3fc7ad5

Taxonomy

Description
This compound belongs to the class of organic compounds known as phenylpyrrolidines. These are polycyclic aromatic compounds containing a benzene ring linked to a pyrrolidine ring through a CC or CN bond. Pyrrolidine is a five-membered saturated aliphatic heterocycle with one nitrogen atom and four carbon atoms.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Pyrrolidines
Sub Class
Phenylpyrrolidines
Direct Parent
Phenylpyrrolidines
Alternative Parents
Pyrrolidine-2-ones / N-substituted carboxylic acid imides / N-alkylpyrrolidines / Benzene and substituted derivatives / Pyrroles / Dicarboximides / Lactams / Azacyclic compounds / Organopnictogen compounds / Organonitrogen compounds
show 3 more
Substituents
3-phenylpyrrolidine / Monocyclic benzene moiety / Carboxylic acid imide, n-substituted / Pyrrolidone / 2-pyrrolidone / N-alkylpyrrolidine / Benzenoid / Carboxylic acid imide / Dicarboximide / Pyrrole
show 12 more
Molecular Framework
Aromatic heteromonocyclic compounds
External Descriptors
Not Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Scaffold protein binding
Specific Function
Voltage-sensitive calcium channels (VSCC) mediate the entry of calcium ions into excitable cells and are also involved in a variety of calcium-dependent processes, including muscle contraction, hor...
Gene Name
CACNA1G
Uniprot ID
O43497
Uniprot Name
Voltage-dependent T-type calcium channel subunit alpha-1G
Molecular Weight
262468.62 Da
References
  1. Gomora JC, Daud AN, Weiergraber M, Perez-Reyes E: Block of cloned human T-type calcium channels by succinimide antiepileptic drugs. Mol Pharmacol. 2001 Nov;60(5):1121-32. [PubMed:11641441]
  2. Coulter DA, Huguenard JR, Prince DA: Characterization of ethosuximide reduction of low-threshold calcium current in thalamic neurons. Ann Neurol. 1989 Jun;25(6):582-93. [PubMed:2545161]
  3. Wang G, Thompson SM: Maladaptive homeostatic plasticity in a rodent model of central pain syndrome: thalamic hyperexcitability after spinothalamic tract lesions. J Neurosci. 2008 Nov 12;28(46):11959-69. doi: 10.1523/JNEUROSCI.3296-08.2008. [PubMed:19005061]
  4. Matthews EA, Dickenson AH: Effects of ethosuximide, a T-type Ca(2+) channel blocker, on dorsal horn neuronal responses in rats. Eur J Pharmacol. 2001 Mar;415(2-3):141-9. [PubMed:11274992]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
General Function
Steroid hydroxylase activity
Specific Function
Responsible for the metabolism of a number of therapeutic agents such as the anticonvulsant drug S-mephenytoin, omeprazole, proguanil, certain barbiturates, diazepam, propranolol, citalopram and im...
Gene Name
CYP2C19
Uniprot ID
P33261
Uniprot Name
Cytochrome P450 2C19
Molecular Weight
55930.545 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]

Drug created on October 30, 2007 19:03 / Updated on June 02, 2018 07:38